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MicroRNAs (miRNAs) are emerging as a novel class of non-coding RNA molecules that regulate gene expression at
a post-transcriptional level. More than 1000 miRNAs have been identified in human cells to date, and they are
reported to play important roles in normal cell homeostasis, cell metastasis and disease pathogensis and
progression. MiR-125, which is a highly conserved miRNA throughout diverse species from nematode to humans,
consists of three homologs hsa-miR-125a, hsa-miR-125b-1 and hsa-miR-125-2. Members of this family have been
validated to be down-regulated, exhibiting its disease-suppressing properties in many different types of diseases,
while they also have disease-promoting functions in certain contexts. MiR-125 targets a number of genes such as
transcription factors, matrix-metalloprotease, members of Bcl-2 family and others, aberrance of which may lead to
abnormal proliferation, metastasis and invasion of cells, even carcinomas. Furthermore, miR-125 plays a crucial role
in immunological host defense, especially in response to bacterial or viral infections. In this review, we summarize
the implication of miR-125 family in disease suppression and promotion, focusing on carcinoma and host immune
responses. We also discussed the potential of this miRNA family as promising biomarkers and therapeutic targets
for different diseases in future.
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MicroRNAs (miRNAs) are a family of ~22 nucleotide (nt)
small noncoding RNAs that act as crucial posttranscrip-
tional regulators of gene expression through translational
repression or transcript cleavage [1]. Since miRNAs were
first described as endogenous mediators in C. elegans in
1993 [2], they have been identified to be involved in
the regulation of numerous cellular processes, including
cell differentiation, proliferation, apoptosis and metabolic
homeostasis [3]. In the past decade, more and more stud-
ies have demonstrated that aberrant expression of miR-
NAs is tightly related to the pathogenesis of diseases,
including almost all types of human cancers [4]. A grow-
ing body of studies elucidate that miRNAs can function as
either tumor suppressors by down-regulating oncogenic
targets, or tumor promoters through negatively regulating
tumor-suppressive target mRNAs [5]. Because of aberrant* Correspondence: lsscyq@mail.sysu.edu.cn
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reproduction in any medium, provided the orexpression of miRNAs in almost all types of cancers and
other diseases, they can possibly be used as biomarkers for
early diagnosis of cancers and other diseases, depending
on their abundance. In addition, miRNAs and their target
genes supply to a general or personalized therapy with
pharmaceutical targets, showing their remarkable value in
clinical therapy.
Among the most important miRNA families, miR-125
family has been reported to be implicated in a variety of
carcinomas and other diseases as either repressors or
promoters. MiR-125 family is composed of three homo-
logs hsa-miR-125a, hsa-miR-125b-1 and hsa-miR-125-2.
MiR-125a has been found to be located at 19q13, while
miR-125b is verified to be transcribed from two loci located
on chromosomes 11q23(hsa-miR-125b-1) and 21q21
(hsa-miR-125b-2) [6]. Furthermore, miR-125b-1 is impli-
cated in some chromosomal translocations like t(11;14)
(q24;q32) and t(2;11)(p21;q23) which leads to B-cell acute
lymphoid leukemia (B-ALL) or myelodysplasia and acute
myeloid leukemia (AML), respectively [7-10]. Members of
the family play crucial roles in many different cellular pro-
cesses like cell differentiation, proliferation and apoptosis. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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matrix-metalloprotease [12,13], growth factors [14] and so
on. The theme of the present paper, however, is to
summarize the function of miR-125 family in different
contexts, particularly in disease condition. We mainly
focus on following four aspects: (1) the regulation of miR-
125 at post-transcription level, (2) the function of miR-
125 as tumor-suppressive or tumor-promoting properties,
(3) potential acting of miR-125 as biomarker, and its possi-
bility to be used as a therapeutic target in disease therapy,
and (4) the immune-modulating functions of miR-125 and
the involvement of this miRNA in immune responses to
pathogen infections.
Involvement of the miR-125 family in solid tumors
A great amount of studies have investigated the relation-
ships between miRNAs and malignancies, and the results
show that miRNA deregulation is involved in all types of
cancer. The different members of miR-125 family have
been reported controversial properties in different types of
cancer; they may contribute to the initiation and progres-
sion of cancers by acting as either tumor suppressors or
oncogenes [15-18].
MiR-125 has been shown its tumor-suppressor func-
tions in several cancers including ovarian cancer [16,19],
bladder cancer [20], breast cancer [21-23], hepatocellular
carcinoma [12,24,25], melanoma [26], cutaneous squa-
mous cell carcinoma [13] and osteosarcoma [27]. Wang
et al. reported that miR-125a, activated by EGFR, func-
tions as a metastatic suppressor in lung cancer cells,
inhibiting tumor formation and tube formation [28]. In
breast cancer, miR-125a and miR-125b were reported
down-regulated in biopsy specimens and as tumor sup-
pressors [23,29,30] by mediating the ERBB2 and ERBB3
pathway [22] or by targeting the ETS1 gene [31]. Fur-
thermore, Hajabi et al. found that miR-125b can reduce
the expression of MUC1 oncoprotein, silencing of which in
breast cancer cells with siRNA promotes DNA damage-
induced apoptosis [32]. Ectopic expression of both
miR-125a [12] and miR-125b [25] can inhibit the prolif-
eration and metastasis of hepatocellular carcinoma. Up-
regulated miR-125a significantly inhibits the malignant
phenotypes by repressing the expression of matrix
metalloproteinase 11 (MMP11) and vascular endothe-
lial growth factor A (VEGF-A) both in vitro and in vivo
[12], while the direct targets of miR-125b in miRNA-
induced inhibition of hepatocellular carcinoma cell pro-
liferation are Mcl-1 and IL6R [25].
In contrast to the tumor-suppressive properties men-
tioned above, the members of miR-125 family, especially
miR-125b, also act as oncogene in several cancers. Jiang
and colleagues observed that AN3CA cells, a type II endo-
metrial carcinoma cell line, transfected with miR-125b
mimic showed higher tumorogenesis in comparison toother negative controls in nude mice, suggesting that up-
regulated miR-125b can promote the proliferation and mi-
gration of the disease [18]. In addition, overexpression of
miR-125b has been investigated in several cancers such as
pancreatic cancer [33], prostate cancer [34,35], oligo-
dendroglial cancer [36] and other cancers. Furthermore,
miR-125b has been demonstrated to play a key role in the
initiation and development of prostate cancer through
evaluating the effect of miR-125b on xenograft tumor
growth in transplanted mice with PC-346C-miR-125b
cells [35]. Albeit miR-125b has been demonstrated to be
tumor suppressor in breast cancer by down-regulating
ERBB2 and ERBB3 [22], several studies have showed its
property to increase resistance of cancer cells, including
breast cancer cells, to anticancer drug [37], resulting in
subsequent recurrence and metastasis. Surprisingly, in
contrast to tumor-suppressive function in breast cancer
mentioned above, a very recent study by Tang et al. has
verified that miR-125b also induces metastasis of human
breast cancer cells through targeting STARD13 [38]. miR-
125a also enhances invasive potential in urothelial carcin-
omas [39] and is up-regulated in basal cell carcinoma
compared with adjacent nonlesional skin [40], while miR-
125b suppresses Bmf-dependent apoptosis in human glio-
blastoma multiforme cells [41].
The controversial properties of the miR-125 family in
different solid tumors suggest that miR-125 plays diverse
functions in cancer pathogenesis and progression, while
the underlying mechanisms on different cell context
need further investigation.
Properties of the miR-125 family in hematological
malignancies
Dysregulation of miRNAs has now clearly been linked to
hematological malignancies, especially to leukemia [42].
It has been shown that miR-125b is implicated in some
subtypes of leukemia induced by chromosomal trans-
location. The chromosomal translocation t(11;14)(q24;
q32) found in patients with B-cell acute lymphoblastic
leukemia (ALL)[7,9] leads to an up-regulation of miR-
125b. Moreover, overexpression of miR-125b also occurs
in patients with myelodysplasia and acute myeloid
leukemia (AML) carrying the t(2;11)(p21;q23) transloca-
tion [8]. MiR-125b has also been reported to be overex-
pressed in megakaryoblastic leukemia [43] and APL [44].
Bousquet and colleagues transplanted fetal liver cells
which ectopic express miR-125b into nude mice to de-
cipher oncogenic mechanism of miR-125b [15]. In this
study they found a higher level of miR-125b increased
white blood cell count in mice and half of these mice
died of diverse leukemia such as B-cell and T-cell ALL,
or a myeloproliferative neoplasm, suggesting miR-125b
an important role in early hematopoiesis (the function
then was proved by Chaudhuri [45]). Furthermore, this
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latency of BCR-ABL induced leukemia as a secondary
event. Enomoto et al. reported that transduction of miR-
125b-1 in bone marrow cells indeed accelerated myeloid
tumors induced by a C-terminal mutant of CAAT-
enhancer binding protein (C/EBPα-C(m)) [46], suggest-
ing that overexpression of miR-125b collaborates with
other genetic alterations in the pathogenesis of myeloid
malignancies. Albeit Enomoto didn’t find leukemia
transformation in their model, a recent study by Bousquet
has highlighted the transformation of miR-125b-induced
leukemia in nude mice [11]. Much to our surprise, miR-
125b, which has been shown reduced expression in both
aggressive and indolent chronic lymphocytic leukemias
(CLL) patients, its overexpression can change metabolic
pathways including glucose, glutathione, lipid and glycero-
lipid metabolism in CLL, suggesting that miR-125b plays a
vital role for the adaptation of cell metabolism to a trans-
formed state [47]. However, the mechanism underlying
differential expression pattern of miR-125b between CLL
and other types of hematological malignancies is still un-
known. We speculated that the induced expression of
miR-125b in CLL leads to metabolic adaptation associated
cancer transformation may be caused by very low prolif-
erative index and defects in apoptotic pathways in the dis-
ease, while the up-regulated miR-125b leads to acute
leukemia may be resulted from hematopoietic stem cell
differentiation block by miR-125b. These speculations
need to be further validated.
The functional link of the miR-125 family in autoimmune
diseases
The aberrant expression of miR-125 was also found in dif-
ferent diseases other than cancers, such as autoimmune
diseases [48]. For instance, miR-125a has been identified
down-regulated in systemic lupus erythematosus (SLE),
and negatively regulated expression of the inflammatory
chemokine RANTES, which is highly expressed in SLE
samples and plays a key role in inflammatory progress
[49]. MiR-125a was also reported to be significantly up-
regulated in macrophases following oxidized low density
lipoprotein (oxLDL) [50], inducing the formation of ische-
mic stroke [51]. Moreover, miR-125b acting as pro-
inflammation role can be mediated by metal sulfates to
affect the outcome of ischemic stroke [51,52]. Interest-
ingly, Zhang and colleagues have found the overexpres-
sion of miR-125b in eosinophilic chronic rhinosinusitis
with nasal polyps, enhancing type I IFN expression
through suppressing 4E-BP1 protein expression [53]. In
addition, dysregulation of miR-125b has been reported to
be involved in Alzheimer's disease [54] and Myotonic Dys-
trophy Type 2 [55]. All together suggest that miR-125
plays important roles in autoimmune diseases. However,
thus far, most of the studies on autoimmune diseasesmainly focus on the expression pattern of miR-125, the
targets and inflammatory pathway in this disease still need
to be declared
MiR-125 involved in immune system development and
immunological host defense
It has been uncovered that miRNAs are tightly asso-
ciated with immune system by controlling the destiny of
immune cells [56,57], regulating the expression of target
encoding genes, responding to stimulatory cues, and en-
hancing the response of immune cells to potential anti-
gen as well as playing a key role in fate of immune cells.
An example is that, B lymphocyte-induced maturation
protein-1 (BLIMP-1) and IFN regulatory protein-4 (IRF4)
transcription factors, which are essential for plasma cell
differentiation, have been demonstrated to be targets for
miR-125b. Gururajan and colleagues have evaluated the
effect of overexpression of miR-125b on B cell differenti-
ation in an LPS-responsive B cell line, finding that miR-
125b can repress the differentiation of primary B cell, in
which they found that miR-125b promotes B lymphocyte
diversification in germinal centers by inhibiting premature
utilization of essential transcription factors for plasma cell
differentiation [56]. In addition, miR-125b is confirmed to
protect B cells from apoptosis through contributing to
repression of BCL2 which does a developmental stage-
specific regulation during B-cell maturation, and deregula-
tion of miR-125b in response to CD40 ligand (CD154) can
lead to proliferation in leukemic B cells [57].
Beyond regulated by cytokine like IL-4 [58] and inter-
feron, miR-125b have also been verified to frequently
regulate expression of signals involved in immune sys-
tem. Studies have showed that up-regulated expression
of miR-125b may enhance type I IFN expression in air-
way epithelial cells in eosinophilic chronic rhinosinusitis
with nasal polyps [53], while negatively regulating TNF-
α expression in neonatal monocytes[59]. Both signals
play crucial roles in immunological host defense, aber-
rant expression or response of which may result in fatal
diseases. Furthermore, overexpression of miR-125b in
macrophage showed the repression to IFN regulatory
factor 4 (IRF4), and elevated responsiveness to IFN-γ,
potentiating the functional role of macrophages in indu-
cing immune responses [60].
Another important function of miR-125 is in immune
responses to bacterial infection, and even shows to par-
take in damage accompanied by pathogenic bacteria.
Rajaram has illustrated that virulent mycobacterium tu-
berculosis could take advantage of miR-125b to block
TNF biosynthesis. Lipomannan from virulent mycobac-
terium tuberculosis induces overexpression of miR-125b,
which subsequently binds to the 3' UTR region of TNF
mRNA and destabilizes the transcript [61]. Apart from
immune reaction to bacterial infection, a study shows
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defense [62]. MiR-125a interacted with the viral sequence
and markedly suppressed the reporter activity. Subse-
quently miR-125a was shown to interfere with the viral
translation, down-regulating the expression of the surface
antigen [62]. Interestingly, miR-125b has been verified to
contribute to HIV-1 latency [63], acting as an anti-HIV-1
miRNA [64]. MiR-125b, repressing HIV-1 activity, is
higher expressed in resting CD4+ T cells in comparison to
activated CD4+ T cells. The miRNA can bind to the 3'
ends of HIV-1 messenger RNAs, leading to destabilization
of the transcript, terminally inhibits HIV-1 production
and prolongs HIV-1 latency in resting CD4+ T cells [63].
In addition, a recent study has found that morphine was
shown to down-regulate the expression of anti-HIV miR-
NAs including miR-125b in cultured human monocytes
[64], which suggests that morphine may have potential to
activate latent HIV-1 in resting CD4+ T cells and macro-
phages by inhibiting related miRNAs expression.
In conclusion, miR-125 family plays crucial roles in
immune system development and immunological host
defense, including regulating differentiation of immune
cells, responding to stimulatory cues in many different
signal pathways involved in immune system, controlling
expression of target genes, products of which partake in
immune reactions as well as in immune responses to
bacterial infection and to viral infection.
The regulatory network of miR-125 family in disease
pathogenesis
As previous reported, miR-125 family plays an important
role in normal cell homeostasis, cell metastasis and dif-
ferent diseases. Current progression also revealed a
number of the miR-125 family target genes and their
regulation pathways, which could supply the feasibility
of using miR-125 as a therapeutic strategy to suppress
diseases.
Members of Bcl-2 family and ones else involved in
apoptosis are an important group of miR-125 targets.
Anti-apoptotic members of Bcl-2 family such as Bcl-w
[65], Bcl-2 [66], Mcl-1 [65,67], and Bak-1 [11,44,68,69]
acting as the Bcl-2 homologous antagonist, and others
involved in apoptosis like P53 [69], TP53INP1 [11,18],
TNFAIP3 [70], p38α [71] et al., have all been demon-
strated to be direct targets of miR-125 in previous studies.
Aberrant expression of miR-125 leads to up-regulation of
Bcl-2, Mcl-1 et al. and down-regulation of Bak-1,
TP53INP1 et al. and consequently to protect cells from
apoptosis, which in turn promotes tumorigenesis. Besides,
p38α expression repressed by miR-125b is required for
protecting cells from UV-induced apoptosis.
ERBB2, which enhances kinase-mediated activation of
downstream signaling pathways such as MAPK, has
been verified to be the target for both miR-125a andmiR-125b [22]. Experimentally, miR-125-induced down-
regulation of ERBB2 and ERBB3 has been uncovered to
reduce cell motility and invasiveness of numerous can-
cers, including breast cancer [22] and endometrial can-
cer [72].
Among other targets of miR-125 associated with pro-
liferation, metastasis and migration, HuR [73], Rock-1
[74], PDPN [75], STAT3 [27] and STARD13 [38] are five
important genes identified, which can induce cell metas-
tasis and migration, and in turn enhance tumorigenesis.
Furthermore, CBFβ, a transcriptional factor involved in
hematopoiesis, which has been confirmed to be a new dir-
ect target of miR-125b, and ABTB1, an anti-proliferative
factor targeted by miR-125b, also contribute to block
differentiation and proliferation in leukemia, respect-
ively [11,76].
Other targets have been demonstrated including matrix-
metalloprotease MMP11[12], MMP13 [13], Kurppel-like
factor KLF13 [49], c-Jun [26], ARID3B(AT-rich interactive
domain 3B) [16,77], ARID3A (AT-rich interactive domain
3A) [78], germ layer specification [79] and hematopoiesis
regulator LIN28A [45], growth factors such as VEGF-A
[12] and IGF-II [14], and growth factor receptors like
FGFR2 [80], et al.
It is necessary to mention that the same target may
have different functions in different cellular processes,
cellular context, and diseases. For example, ARID3B ele-
vates the epithelial-to-mesenchymal transition (EMT) in
human ovarian cancer [16], while increases cell migra-
tion in breast cancer [77]. Consequently, target genes of
specific cell-type may be useful in a more targeted and
precise therapy by miRNAs.
As summarized in Figure 1, the targets of miR-125
family are involved in different types of diseases patho-
genesis. MiR-125 can act as cancer promoter or cancer
repressor depends on the cell context, among which, the
mitochondrial apoptosis pathway is the well illustrated
role of miR-125 with the two faces (as shown in Figure 2).
The down regulated miR-125 caused breast cancer but
the up regulated miR-125 induced chemoresistance,
and higher expression of miR-125 promoted ALL or
AML nevertheless reduced expression of miR-125b
resulted in metabolic pathways transformed in CLL. Re-
search on miR-125 in leukemia and breast cancer
model may provide a new insight into current miRNA
research.
Potential of miR-125 for disease diagnosis and therapy
Some protein coding genes have been reported playing
critical roles in tumor initiation and progression, and
their expression levels are correlated with clinical out-
come [81,82]. Growing studies demonstrate the advan-
tages using miRNA as biomarkers for cancer and
disease. The reviews above have shown that expression
Figure 1 Schematic diagram of the targets of miR-125 involved in different types of disease pathogenesis.
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of disease, implying that the miR-125 could predict dis-
ease onset and might potentially serve as prognostic
marker in disease-derived tissues and possibly in serum.
For example, decreased miR-125a has been observed in
hepatocellular carcinoma (HCC) tissues compared with
matched adjacent liver tissues, and associated with
patients' aggressive pathologic features [12]. Moreover,
Hong and colleagues have uncovered that the expression
levels of miR-125b were much lower in HCC tissues
than in non-tumor liver tissues [25], indicating that both
miR-125a and miR-125b have low expression level andFigure 2 The targets of miR-125 in mitochondrial apoptosis
pathway. MiR-125 plays important roles in mitochondrial apoptosis
pathway by targeting pro-apoptosis or anti-apoptosis gene depends
on the cell context.are inversely correlated with aggressiveness and poor
prognosis in HCC, and could serve as the bio-marker
for HCC diagnosis and prognosis. Expression profiling
of miR-125b is a potential marker for thyroid cancer as
it is overexpressed in thyroid cancer and its level has
remarkably distinction between benign and malignant
thyroid neoplasms [83]. In human colorectal cancer,
Nishida and colleagues have evaluated expression of
miR-125b in 89 colorectal cancer cases, and interestingly
found that the high miR-125b expression group not only
showed a greater incidence of advanced tumor size and
tumor invasion, but also had a significantly poorer prog-
nosis compared to the low expression group [84], sug-
gesting that miR-125b could be an important prognostic
marker for colorectal cancer patients. The miRNA de-
regulation may be also associated with clinical relevance
linking to key gene mutations [85]. For example, down-
regulation of miR-125b was found significant correlation
with TP53 mutation status [86]. Taken together, miR-
125 family has great perspective as a diagnostic and
prognostic biomarker. More importantly, a great amount
of studies have demonstrated that circulating miRNAs in
human serum and other body fluids can be used as bio-
markers for cancer and other diseases [87,88]. This po-
tential of miRNAs provides a possibility to carry out
non-invasive analyses to clinicians, which can be per-
formed easily in a large number of clinical samples.
However, standard reference controls are needed in
order to ensure reliable and correct measurements of
miRNA levels.
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tential of the miRNA associated with therapy [89,90]. As
mentioned above, miR-125 family may contribute to the
initiation and progression of diseases by acting as either
suppressors or promoters in a number of cancers and
other diseases [16,17,22,23,25,28,29], re-introduction of
synthetic miR-125 or its antisense at specific sites could
become a possible treatment option.
Conclusions
Evidences deriving from the increasing number of
papers showed that members of miR-125 family play a
crucial role in diverse cellular processes and many dis-
eases especially carcinomas. It is noteworthy that the
functions of miR-125 are controversial in different types
of diseases. In certain contexts, miR-125 can down-
regulate target oncogene as a tumor suppressor, redu-
cing tumor proliferation and metastasis. Vice versa, a
variety of studies have exhibited tumor-promoting func-
tions of miR-125 as a tumor promoter. The advances
that miR-125 and other miRNAs can be used in clinical
applications exactly hold potential for future treatment
of diseases. Furthermore, an increasing number of stud-
ies have identified the target genes of miR-125 family in
different cellular contexts, which highlights the precise
properties of this miRNA in cellular pathways and net-
works, especially associated with carcinoma. Moreover,
miR-125 influences the fate of immune cells by targeting
and regulating a set of target genes to enhance the effect
against intra- or extracellular pathogens, or responding
to the regulation of specific signal stimulation like IL
and IFN. Since aberrant expression of miRNAs exist in
almost all types of cancers and several other diseases,
the potential use of miR-125 as potent prognostic mar-
kers for early diagnosis of malignancies and other dis-
eases has drawn more and more attentions. In addition,
in accordance with either disease-suppressive or - pro-
moting properties of miRNAs in different diseases, miR-
125’s ability as therapeutic agents has been delineated by
many research groups. Further research is needed before
miR-125 and other miRNAs can be used in clinical
applications.
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